Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Presentation to Include Update on Coronavirus (COVID-19) Vaccine Program ATLANTA, GA, Feb. 27, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTC: GOVX), a biotechnology company...
-
Company Comments on NIH/NIAID Discontinuance of Sanofi/GSK HVTN 702 Trial ATLANTA, GA, Feb. 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTC: GOVX) (OTC: GOVXD), a...
-
Company Comments on NIH/NIAID Discontinuance of Sanofi/GSK HVTN 702 Trial ATLANTA, GA, Feb. 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTC: GOVX), a biotechnology...
-
ATLANTA, GA, and WUHAN, CHINA, Jan. 27, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTC: GOVXD), a biotechnology company developing human immunotherapies and vaccines against...
-
1:2000 Reverse Split Effective January 24, 2020;Ticker Symbol Changed to GOVXD for 20 Days ATLANTA, GA, Jan. 23, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – GeoVax Labs, Inc. (OTC: GOVX) today...
-
Two Separate Presentations to Focus on the Company’s Infectious Disease Vaccines and Cancer Immunotherapy Programs ATLANTA, GA, Dec. 03, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs,...
-
Developing Multiple Strategies Toward Ending the HIV/AIDS Epidemic ATLANTA, GA, Dec. 02, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTC: GOVX), a biotechnology company...
-
Presentation to Focus on the Company’s MVA-VLP Platform for Safe and Effective Vaccines for Infectious Diseases and Cancer ATLANTA, GA, Nov. 14, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax...
-
Clinical Trial Expected to Commence in Early 2020 ATLANTA, GA, Nov. 13, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX) announced today its participation in a...
-
GeoVax Vaccine To Be Used in a Phase 1 Trial of Genetically Modified Autologous Cell Therapy for HIV
IND Application Submitted to FDA for Phase 1 Trial ATLANTA, GA, Oct. 24, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – GeoVax Labs, Inc. (OTCQB: GOVX) announced today its participation in a...